MHRA 发布 Class 3 药品召回:Sun Pharmaceutical 阿托伐他汀 20mg 与 80mg 薄膜衣片 EL(25)A/48
Class 3 Medicines Recall: Sun Pharmaceutical Industries Limited, Atorvastatin 20mg and 80mg Film-coated Tablets, EL(25)A/48
MHRA 缺陷药品报告中心发布 Class 3 药品召回,Sun Pharma UK Limited 以预防性措施召回阿托伐他汀 20mg 和 80mg 薄膜衣片的特定批次,原因是持续稳定性研究中出现溶出度检测结果不合格。
通报列出两个规格的受影响批次、有效期与首次分销日期,并说明召回源于稳定性研究中的溶出度检测结果不合格。
Contents
- DMRC reference number
- Marketing Authorisation Holder
- Medicine Details
- Affected Lot Batch Numbers
- Medicine Details
- Affected Lot Batch Numbers
- Background
- Advice for Healthcare Professionals
- Advice for Healthcare Professionals to Provide to Patients
- Additional information
- Download document
DMRC reference number
DMRC - 37494064
Marketing Authorisation Holder
Sun Pharmaceutical Industries Limited
Medicine Details
Atorvastatin 20 mg Film-coated Tablets
PL: 14894/0714
Active Ingredient: atorvastatin calcium trihydrate
SNOMED code: 22940911000001103
GTIN: 05015525012327
Affected Lot Batch Numbers
| Batch No. | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| PTF6133A | 30/11/2027 | 28 | 09/09/2025 |
Medicine Details
Atorvastatin 80 mg Film-coated Tablets
PL:14894/0716
Active Ingredient: atorvastatin calcium trihydrate
SNOMED code: 22941511000001103
GTIN: 05015525012341
Affected Lot Batch Numbers
| Batch No. | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| PTF5991D | 30/11/2027 | 28 | 19/08/2025 |
| PTF5991F | 30/11/2027 | 28 | 27/08/2025 |
Background
Sun Pharma UK Limited are recalling the batches of tablets specified in the table as a precautionary measure due to failing dissolution test results reported during ongoing stability studies.
Advice for Healthcare Professionals:
Stop supplying the above batches immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.
Advice for Healthcare Professionals to Provide to Patients:
Patients should continue to take medicines as prescribed by your healthcare professional. The recall is being actioned at the wholesaler level as a precautionary measure. No complaints of harm or lack of efficacy have been received from patients regarding this batch.
Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.
Additional information:
For all medical information enquiries and information on this product, please email [email protected], or telephone 020 8848 5050 / 07974754551.
For stock control enquiries please email [email protected], or telephone 020 8848 5050.
Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
Yours faithfully
Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
Download document
来源:MHRA 药品召回与缺陷通报 · gov.uk